Mural Oncology Stock
Mural Oncology Stock price
Key metrics
| Market capitalization | $59.46m |
| Enterprise Value | $-134.16m |
| P/E (TTM) P/E ratio | negative |
| P/B ratio (TTM) P/B ratio | 0.29 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-160.92m |
| Cash position | $204.70m |
| EPS (TTM) EPS | $-9.14 |
| P/E forward | negative |
Is Mural Oncology a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
Mural Oncology Stock Analysis
Analyst Opinions
4 Analysts have issued a Mural Oncology forecast:
Analyst Opinions
4 Analysts have issued a Mural Oncology forecast:
Financial data from Mural Oncology
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -3.26 -3.26 |
-
|
|
| EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -161 -161 |
-
|
| Net Profit | -154 -154 |
-
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Mural Oncology directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mural Oncology Stock News
Company Profile
Mural Oncology Plc operates as a clinical stage company. It focus on discovering and developing immuno therapies that may meaningfully improve the lives of patients with cancer. Its portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The company was founded in May 2017 and is headquartered in Dublin, Ireland.
| Head office | Ireland |
| CEO | Caroline Loew |
| Employees | 117 |
| Founded | 2017 |
| Website | www.muraloncology.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
